459 related articles for article (PubMed ID: 28922609)
1. Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm).
Chan GG; Koch CM; Connors LH
J Proteome Res; 2017 Nov; 16(11):4104-4112. PubMed ID: 28922609
[TBL] [Abstract][Full Text] [Related]
2. Blood Proteomic Profiling in Inherited (ATTRm) and Acquired (ATTRwt) Forms of Transthyretin-Associated Cardiac Amyloidosis.
Chan GG; Koch CM; Connors LH
J Proteome Res; 2017 Apr; 16(4):1659-1668. PubMed ID: 28196416
[TBL] [Abstract][Full Text] [Related]
3. The transthyretin amyloidoses: advances in therapy.
Dubrey S; Ackermann E; Gillmore J
Postgrad Med J; 2015 Aug; 91(1078):439-48. PubMed ID: 26048914
[TBL] [Abstract][Full Text] [Related]
4. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
[TBL] [Abstract][Full Text] [Related]
5. Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.
Kurian SM; Novais M; Whisenant T; Gelbart T; Buxbaum JN; Kelly JW; Coelho T; Salomon DR
Theranostics; 2016; 6(11):1792-809. PubMed ID: 27570551
[TBL] [Abstract][Full Text] [Related]
6. Serum transthyretin monomer in patients with familial amyloid polyneuropathy.
Sekijima Y; Tokuda T; Kametani F; Tanaka K; Maruyama K; Ikeda S
Amyloid; 2001 Dec; 8(4):257-62. PubMed ID: 11791618
[TBL] [Abstract][Full Text] [Related]
7. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.
Sattianayagam PT; Hahn AF; Whelan CJ; Gibbs SD; Pinney JH; Stangou AJ; Rowczenio D; Pflugfelder PW; Fox Z; Lachmann HJ; Wechalekar AD; Hawkins PN; Gillmore JD
Eur Heart J; 2012 May; 33(9):1120-7. PubMed ID: 21992998
[TBL] [Abstract][Full Text] [Related]
8. Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach.
Tasaki M; Ueda M; Obayashi K; Koike H; Kitagawa K; Ogi Y; Jono H; Su Y; Suenaga G; Oshima T; Misumi Y; Yoshida M; Yamashita T; Sobue G; Ando Y
Int J Cardiol; 2013 Dec; 170(1):69-74. PubMed ID: 24182678
[TBL] [Abstract][Full Text] [Related]
9. [Application to transthyretin analysis].
Ueda M; Ando Y
Rinsho Byori; 2006 Jun; 54(6):601-8. PubMed ID: 16872010
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.
Sekijima Y; Ueda M; Koike H; Misawa S; Ishii T; Ando Y
Orphanet J Rare Dis; 2018 Jan; 13(1):6. PubMed ID: 29343286
[TBL] [Abstract][Full Text] [Related]
11. A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.
Jimenez-Zepeda VH; Bahlis NJ; Gilbertson J; Rendell N; Porcari R; Lachmann HJ; Gillmore JD; Hawkins PN; Rowczenio DM
Amyloid; 2015 Mar; 22(1):26-30. PubMed ID: 25430583
[TBL] [Abstract][Full Text] [Related]
12. Evidence of the presence of amyloid substance in the blood of familial amyloidotic polyneuropathy patients with ATTR Val30Met mutation.
Liu J; Lan J; Zhao P; Zheng F; Song J; Zhang P; Sun X
Int J Clin Exp Pathol; 2014; 7(11):7795-800. PubMed ID: 25550818
[TBL] [Abstract][Full Text] [Related]
13. Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy.
Palha JA; Moreira P; Olofsson A; Lundgren E; Saraiva MJ
J Mol Med (Berl); 2001; 78(12):703-7. PubMed ID: 11434723
[TBL] [Abstract][Full Text] [Related]
14. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
[TBL] [Abstract][Full Text] [Related]
15. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
[TBL] [Abstract][Full Text] [Related]
16. Late-onset Transthyretin (TTR)-familial Amyloid Polyneuropathy (FAP) with a Long Disease Duration from Non-endemic Areas in Japan.
Miyake Z; Nakamagoe K; Ezawa N; Yoshinaga T; Hashimoto R; Sato T; Sekijima Y; Tamaoka A
Intern Med; 2019 Mar; 58(5):713-718. PubMed ID: 30333406
[TBL] [Abstract][Full Text] [Related]
17. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
18. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine.
Obayashi K; Tasaki M; Jono H; Ueda M; Shinriki S; Misumi Y; Yamashita T; Oshima T; Nakamura T; Ikemizu S; Anan I; Suhr O; Ando Y
Clin Chim Acta; 2013 Apr; 419():127-31. PubMed ID: 23462670
[TBL] [Abstract][Full Text] [Related]
19. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.
Schmidt HH; Barroso F; González-Duarte A; Conceição I; Obici L; Keohane D; Amass L
Muscle Nerve; 2016 Sep; 54(3):353-60. PubMed ID: 27273296
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M
Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]